메뉴 건너뛰기




Volumn 91, Issue 3, 2012, Pages 555-557

Regulatory innovation in postmarketing risk assessment and management

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CERIVASTATIN; CISAPRIDE; DROSPIRENONE; ETHINYLESTRADIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOCLOPRAMIDE; PIOGLITAZONE; ROSIGLITAZONE; VARENICLINE;

EID: 84857236220     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.289     Document Type: Article
Times cited : (21)

References (21)
  • 2
    • 74249112988 scopus 로고    scopus 로고
    • Prevalence of osteonecrosis of the jaw in patients witHoral bisphosphonate exposure
    • Predicting Risk of Osteonecrosis of the Jaw witHoral Bisphosphonate Exposure (PROBE) Investigators
    • Lo, J.C. et al.; Predicting Risk of Osteonecrosis of the Jaw witHoral Bisphosphonate Exposure (PROBE) Investigators. Prevalence of osteonecrosis of the jaw in patients witHoral bisphosphonate exposure. J. Oral Maxillofac. Surg. 68, 243-253 (2010).
    • (2010) J. Oral Maxillofac. Surg. , vol.68 , pp. 243-253
    • Lo, J.C.1
  • 3
    • 77954988618 scopus 로고    scopus 로고
    • Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
    • Graham, D.J. et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411-418 (2010).
    • (2010) JAMA , vol.304 , pp. 411-418
    • Graham, D.J.1
  • 4
    • 84857237181 scopus 로고    scopus 로고
    • Neuropsychiatric events in varenicline compared to nicotine replacement therapy (NRT) patch users, Military Health System (MHS)
    • Meyer, T.E. et al. Neuropsychiatric events in varenicline compared to nicotine replacement therapy (NRT) patch users, Military Health System (MHS). Pharmacoepidemiol Drug Saf. 20, S245-S246 (2011).
    • (2011) Pharmacoepidemiol Drug Saf. , vol.20
    • Meyer, T.E.1
  • 5
    • 3042623891 scopus 로고    scopus 로고
    • Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy
    • DOI 10.1002/pds.977
    • Chang, J.T., Staffa, J.A., Parks, M. & Green, L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol. Drug Saf. 13, 417-426 (2004). (Pubitemid 38996852)
    • (2004) Pharmacoepidemiology and Drug Safety , vol.13 , Issue.7 , pp. 417-426
    • Chang, J.T.1    Staffa, J.A.2    Parks, M.3    Green, L.4
  • 6
    • 34548827696 scopus 로고    scopus 로고
    • The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs
    • DOI 10.1016/j.contraception.2007.06.002, PII S0010782407003149
    • McAdams, M., Staffa, J.A. & Dal Pan, G.J. The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs. Contraception 76, 278-281 (2007). (Pubitemid 47444286)
    • (2007) Contraception , vol.76 , Issue.4 , pp. 278-281
    • McAdams, M.1    Staffa, J.A.2    Dal Pan, G.J.3
  • 8
    • 13844320866 scopus 로고    scopus 로고
    • Tardive dyskinesia risks and metoclopramide use before and after U.S market withdrawal of cisapride
    • Shaffer, D., Butterfield, M., Pamer, C. & Mackey, A.C. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J. Am. Pharm. Assoc. (2003). 44, 661-665 (2004).
    • (2003) J. Am. Pharm. Assoc. , vol.44 , pp. 661-665
    • Shaffer, D.1    Butterfield, M.2    Pamer, C.3    MacKey, A.C.4
  • 9
    • 34548276415 scopus 로고    scopus 로고
    • Duration of therapy with metoclopramide: A prescription claims data study
    • DOI 10.1002/pds.1397
    • Kaplan, S., Staffa, J.A. & Dal Pan, G.J. Duration of therapy with metoclopramide: a prescription claims data study. Pharmacoepidemiol. Drug Saf. 16, 878-881 (2007). (Pubitemid 47322587)
    • (2007) Pharmacoepidemiology and Drug Safety , vol.16 , Issue.8 , pp. 878-881
    • Kaplan, S.1    Staffa, J.A.2    Dal Pan, G.J.3
  • 10
    • 76149135710 scopus 로고    scopus 로고
    • Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions
    • Pamer, C.A. et al. Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. Pharmacoepidemiol. Drug Saf. 19, 158-174 (2010).
    • (2010) Pharmacoepidemiol. Drug Saf. , vol.19 , pp. 158-174
    • Pamer, C.A.1
  • 11
    • 80051509793 scopus 로고    scopus 로고
    • Changes in topical calcineurin use following regulatory actions in the U.S
    • Moeny, D., La Grenade, L. & Brinker, A. Changes in topical calcineurin use following regulatory actions in the U.S. Pharmacoepidemiol. Drug Saf. 18 (suppl. 1), S180 (2009).
    • (2009) Pharmacoepidemiol. Drug Saf. , vol.18 , Issue.SUPPL. 1
    • Moeny, D.1    La Grenade, L.2    Brinker, A.3
  • 16
    • 78751688048 scopus 로고    scopus 로고
    • Advancing the science for active surveillance: Rationale and design for the Observational Medical Outcomes Partnership
    • Stang, P.E. et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann. Intern. Med. 153, 600-606 (2010).
    • (2010) Ann. Intern. Med. , vol.153 , pp. 600-606
    • Stang, P.E.1
  • 17
    • 40949139727 scopus 로고    scopus 로고
    • Estimating the extent of reporting to FDA: A case study of statin-associated rhabdomyolysis
    • DOI 10.1002/pds.1535
    • McAdams, M., Staffa, J. & Dal Pan, G. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiol. Drug Saf. 17, 229-239 (2008). (Pubitemid 351404034)
    • (2008) Pharmacoepidemiology and Drug Safety , vol.17 , Issue.3 , pp. 229-239
    • MacAdams, M.1    Staffa, J.2    Dal Pan, G.3
  • 18
    • 0002656565 scopus 로고
    • Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs
    • Rainsford K.D. & Velo G.P. (eds). Raven Press: New York
    • Weber, J.C.P. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In Advances in Inflammation Research, Rainsford K.D. & Velo G.P. (eds). Raven Press: New York, 1984:1-7.
    • (1984) Advances in Inflammation Research , pp. 1-7
    • Weber, J.C.P.1
  • 19
    • 52949152357 scopus 로고    scopus 로고
    • Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: Revisiting the Weber effect. Pharmacoepidemiol
    • McAdams, M.A., Governale, L.A., Swartz, L., Hammad, T.A. & Dal Pan, G.J. Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect. Pharmacoepidemiol. Drug Saf. 17, 882-889 (2008).
    • (2008) Drug Saf. , vol.17 , pp. 882-889
    • McAdams, M.A.1    Governale, L.A.2    Swartz, L.3    Hammad, T.A.4    Dal Pan, G.J.5
  • 21
    • 80054802888 scopus 로고    scopus 로고
    • Secondary use of randomized controlled trials to evaluate drug safety: A review of methodological considerations
    • Hammad, T.A., Pinheiro, S.P. & Neyarapally, G.A. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations. Clin. Trials 8, 559-570 (2011).
    • (2011) Clin. Trials , vol.8 , pp. 559-570
    • Hammad, T.A.1    Pinheiro, S.P.2    Neyarapally, G.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.